All In Biotech

Drug Trial Radar · NCT07382531

OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors

An Open-label, Dose-escalation Phase Ib/II Clinical Trial of Intratumoral Injection of OH2 Injection in Combination With BS006 Injection for the Treatment of Advanced Solid Tumors.

Last checked: Nov 19, 2026Latest source record: Feb 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Sep 7, 2023

Primary completion

Dec 31, 2027

Study completion Jun 30, 2028

Sponsor

Sponsor type
Industry
First posted
Feb 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

BS008-001 is a multicenter, open-label phase Ib /II trial in heavily pre-treated patients with advanced solid tumors. Patients received biweekly sequential intratumoral injections of OH2 (fixed dose: 10⁷ CCID₅₀/mL) followed by BS006 (dose escalation: 10⁶-10⁷ CCID₅₀/mL), with identical volumes being injected at the same lesion. The primary endpoint is safety and tolerability; secondary endpoints included efficacy outcomes assessed by RECIST 1.1/iRECIST.

Conditions

  • Solid Tumor

Interventions

  • OH2+BS006Biological

    Patients received biweekly sequential intratumoral injections of OH2 (fixed dose: 10⁷ CCID₅₀/mL) followed by BS006 (dose escalation: 10⁶-10⁷ CCID₅₀/mL), with identical volumes being injected at the same lesion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of AE (Adverse Event) and SAE (Serious Adverse Event)Time frame: Through study completion, six months after the last administration of the study drug to the last enrolled subject.
  2. DLTs (Dose Limiting Toxicity)Time frame: 4 weeks from the first administration
  3. MTDTime frame: Through study completion, six months after the last administration of the study drug to the last enrolled subject.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.